Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cataract & MIGS cases in Ohio: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 7% on average (255 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 311 | 79,828 | 47% |
| 2020 | 303 | 66,767 | 50% |
| 2021 |
Cataract extraction with IOL, with and without glaucoma stents; the ASC volume engine. Professional codes (what the surgeon bills): CPT 66984, 66982, 66989, 66991, 66987, 66988, 65820, 66174, 66183, 0671T, 0449T.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 13% of the cases CMS names in Ohio; 151 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Vitreoretinal surgery | 51 | 3,204−1.9%/yr | −1.9%/yr | 2.91.3× | 78% | 3,460 in 2030+1.3%/yr |
Cataract & MIGS in every state, and its device makers · Every procedure market in Ohio · Every state · Compare with Minnesota
| 2024 |
| 74,196 |
| 60% |
| 2025 est. | ≈ 73,600 | – |
| 2026 est. | ≈ 76,200 | – |
| 312 |
| 79,848 |
| 53% |
| 2022 | 312 | 81,713 | 56% |
| 2023 | 311 | 79,062 | 58% |
| 2024 | 292 | 74,196 | 60% |
| 2025 from claims | – | 73,595 67,540–77,864 | 61% |
| 2026 forecast | – | 76,171 67,018–87,898 | 61% |
| 2027 forecast | – | 77,046 65,866–91,815 | 61% |
| 2028 forecast | – | 77,923 65,020–95,415 | 61% |
| 2029 forecast | – | 78,803 64,363–98,826 | 62% |
| 2030 forecast | – | 79,683 63,837–102,113 | 62% |
In 2025, 24% hospital outpatient, 72% surgery center, 4% office. The share outside the hospital has moved +3 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| −0.8%/yr |
| 48.0 |
| 70% |
| 75,800 in 2030+2%/yr |
| Indiana | 139 | 45,606−2.5%/yr | −2.5%/yr | 63.6 | 83% | 44,900 in 2030−0.3%/yr |
| Michigan | 304 | 41,610−7.1%/yr | −7.1%/yr | 48.2 | 76% | 38,700 in 2030−1.2%/yr |
| Wisconsin | 145 | 38,264+1.4%/yr | +1.4%/yr | 66.5 | 58% | 52,200 in 2030+5.3%/yr |
| Missouri | 163 | 35,677−3.1%/yr | −3.1%/yr | 56.5 | 81% | 35,000 in 2030−0.3%/yr |
| Kansas | 67 | 23,142−1.6%/yr | −1.6%/yr | 56.6 | 78% | 24,400 in 2030+0.9%/yr |
| Iowa | 68 | 18,172−5.5%/yr | −5.5%/yr | 40.4 | 61% | 20,600 in 2030+2.1%/yr |
| Nebraska | 48 | 17,332+0.1%/yr | +0.1%/yr | 65.8 | 75% | 20,900 in 2030+3.2%/yr |
| South Dakota | 28 | 11,938−0.1%/yr | −0.1%/yr | 90.9 | 84% | 13,900 in 2030+2.5%/yr |
| North Dakota | 23 | 8,264+1.9%/yr | +1.9%/yr | 82.0 | 78% | 9,110 in 2030+1.6%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Alcon leads with 38% of company spending on these surgeons in 2025, −22 pts on 2024.
In 2025, 20 companies reported engagement with Ohio’s surgeons worth $560K in consulting, speaking, meals and travel tied to these products, about $1,918 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.